1yr
Share
1yr
Obesity-Related Ciliopathies: Focus on Advances of Biomarkers - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39126056/
Obesity-related ciliopathies, as a group of ciliopathies including Alström Syndrome and Bardet-Biedl Syndrome, exhibit distinct genetic and phenotypic variability. The understanding of these diseases is highly significant for understanding the...
This paper reviews obesity-related ciliopathies, like Alström and Bardet-Biedl syndromes, emphasizing primary cilia’s role, clinical variability, and the need for biomarker research to improve diagnosis, prognosis, and treatment insights.
Share
1yr
Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38008609/
The novel term Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is proposed to replace non-alcoholic fatty liver disease (NAFLD) to highlight the close association with the metabolic syndrome. MASLD encompasses patients...
MASLD, replacing NAFLD, links liver steatosis to cardiometabolic risks, with CVD as a leading cause of death. Screening via SCORE2, lifestyle changes, statins, and anti-hypertensives are recommended treatments.
Share
1yr
Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37879540/
Obesity and its comorbidities, including type 2 diabetes mellitus, cardiovascular disease, heart failure and non-alcoholic liver disease are a major health and economic burden with steadily increasing numbers worldwide. The...
The article reviews obesity and its comorbidities, highlighting organ-specific mechanisms, effective treatments like bariatric surgery, emerging pharmacological options, and the potential of targeting the gut-brain axis for future therapies.
Share
1yr
Obesity Management in Adults: A Review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38015216/
Obesity affects approximately 42% of adults in the US. Behavioral interventions can attain approximately 5% to 10% weight loss, GLP-1 agonists and glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists can attain approximately...
Obesity affects 42% of US adults, increasing health risks. Effective treatments include behavioral interventions, GLP-1 agonists, and bariatric surgery, achieving 5-30% weight loss based on individual needs.
Share